A recent study by Nagoya University researchers revealed that microRNAs in urine could be a promising biomarker to diagnose brain tumors. Their findings have indicated that regular urine tests could help early detection and treatment of brain tumors, possibly leading to improved patient survival.
The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) infections.
LMU researchers have identified the 14-3-3sigma gene as an important suppressor of carcinogenesis in the gastrointestinal tract.
A Clemson University researcher has developed a protein which links natural killer cells in the human body's immune system to breast cancer cells. It's a novel approach to developing breast cancer-specific immunotherapy and could lead to new treatment options for the world's most common cancer.
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature in June.
Survival among people with early-onset (diagnosed before age 50) colorectal cancer compared with later-onset colorectal cancer (diagnosed at ages 51 through 55) was compared using data from the National Cancer Database.
Just a small number of cells found in tumors can enable and recruit other types of cells nearby, allowing the cancer to spread to other parts of the body, report Georgetown Lombardi Comprehensive Cancer Center scientists. Working with their research collaborators, the scientists found that 'enabler cells' comprise about 20 percent or less of the cells in an aggressive tumor; their small numbers may account for why they are often missed when bulk tissue analyses are used to inform therapeutic decisions.
In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody. The study was published today online in the Journal of Clinical Investigation Insight.
CNIO researchers have found out how PrimPol protein helps the cell to survive the damage caused by chemotherapy and plan to use this knowledge to enhance cancer treatments.
New results allow the development of novel therapies for hereditary forms of intestinal cancer.